Optimer® – Delivering complete control over affinity ligand design, quality and security of supply

The Optimer® platform delivers next-generation aptamer tools that are enabling researchers and developers across the spectrum of the life sciences. Optimer® binders have been successfully developed for a range of applications, including:

  • therapeutic inhibitors and modulators
  • drug delivery vehicles
  • protein purification and separation
  • biomarker screening and validation
  • in vitro research
  • quality control analysis
  • pharmacokinetic and drug assays
  • in vitro diagnostic assays

Consultation and project design

Sequencing, synthesis and quality control processes to ensure delivery of a functional Optimer.

Target feasibility

Delivers rapid insight into project feasibility for quick go/no-go decisions. Wide range of viable targets:

  • small molecules (drugs, toxins, food additives, environmental contaminants)
  • proteins and peptides (immunoglobulins, serum proteins, membrane proteins, secreted proteins, enzymes, specific protein domains, peptides >20 kDa)
  • viral vectors
  • cells (fixed and live cells in suspension and monolayer culture)
  • tissues (organs, tissues, FFPE sections)

Targets and counter-targets are tested for purity, concentration and optimal buffer compatibility for the selection process.

In vitro selection

Specific proprietary high-throughput selection processes for different target classes:

  • Cells
  • Proteins and peptides
  • Small molecules

Adaptable selection system with the ability to: counter-select against related targets, select in end-use buffer and matrix conditions, select in the presence/ absence of ligands, screen mutant vs wild-type, select for specific binding kinetics and performance.

Clonal analyses & Optimer development

Aptamer pools are assessed for target affinity and the aptamer population is cloned out. Individual clones are isolated from the population for next-generation sequencing to determine the diversity in the aptamer repertoire. Individual aptamers are ranked according to target affinity by biolayer interferometry or other project-defined criteria. Target affinity of the best aptamer clone is increased and cost-effective manufacture ensured via identification of the minimal performing fragment of the aptamer to generate an Optimer.

Assay development

Optional services from proof-of-concept to a defined and functional assay. Range of assays available in-house, including ELISA, flow cytometry, cell-based inhibition/activation assays, affinity chromatography, WB, SPR, fluorescence microscopy and IHC.


Sequencing, synthesis and quality control processes to ensure delivery of a functional Optimer.

Want to talk to the team?